IFI-M · UBK Tri-Axis Balanced Series

Specimen SS-F-M3-02569 // MULTI-AXIS · IFI-M

UBK Tri-Axis Balanced Series IV-IV

Solanum lycopersicum

Tomato

Tier IVUBK Tri-Axis Balanced Series

Target Trait

2.13×

fold-change

Umami+Bitter-Attenuation+Kokumi balanced tri-axis fold-change

Technical Specifications

SKU

SS-F-M3-02569

Genomic Edits

10

GC Content

47.8%

Construct Length

5,659 bp

Promoter System

T7/SP6 cell-free

Expression System

In-vitro cell-free

Host Strain

Cell-free

Receptor Target

mGluR1 + TAS2R38 (suppression) + CaSR

IFI Score

213

Pathway Edits

  • mGluR1 pathway primary gene cluster for umami (IFI-U) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • CaSR pathway primary gene cluster for kokumi (IFI-K) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent UBK pathway operation
  • Cross-pathway regulatory circuit for balanced UBK triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: mGluR1, TAS2R38 (suppression), and CaSR pathways simultaneously engineeredBalanced tri-axis expression strategy (UBK) with cross-pathway flux managementCell-free co-translation of multi-axis enzyme sets for in-vitro biochemical validation

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier IV UBK triple-axis construct for advanced multi-modal sensory architecture combining umami, bitter-attenuation, and kokumi axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$3999 · Tier IV License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Multi-Axis · IFI-MAll Modalities